Crowdonomics
All companies
HOPE-Neuron Therapeutx, Inc. logo

HOPE-Neuron Therapeutx, Inc.

Raising nowOperating

Hope- Neuron Therapeutx, Inc

Biotech · Phoenix, AZ · Founded 2023

Hope-Neuron Therapeutx is developing SELtx, a device-enabled therapy that treats a patient's own blood outside the body and reinfuses it to rebalance the immune system, without infused drugs. It is aimed first at ALS, has shown results in ALS mice, and plans human trials.

Raising nowRaising now on Republic

This company has an open fundraising round.

$18K raised6 investors49 days left
View the live round
Latest valuation
—
No round has disclosed a priced valuation or cap.
Total raised
$17,600
Across 1 round since 2026
Latest share price
$1.00
Reg CF · Common Stock · Jul 2026 offering price

Financials

FY2024–FY2025 · from SEC filings · hover any figure for its source
$0
−$63K
2024
$0
−$56K
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2024 audited
FY2025 audited
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$63,474
-$56,126
Taxes paid
$0
$0
Balance sheet
Cash
$19,252
$19,213
Accounts receivable
$0
$0
Total assets
$19,252
$19,213
Short-term debt
$0
$0
Long-term debt
$0
$0
Total liabilities
$0
$0
Other
Headcount
—
5

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Fundraising history

Raised $17.6K / $5MInvestors 6

Team

2 people
Ronald Lane
Chief Executive Officer and Executive Chairman
Karina Fedasz
Interim CFO

Names and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not obligated

never closed a Reg CF raise

5 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form CJul 30, 20260002114933-26-000001
    EDGAR
Source: SEC EDGARCIK 0002114933DEShare price $1.00Last synced Aug 17, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.